Red Flags Detected

  • Material Weakness (worsened) — Material weakness now specifically tied to acquisition transactions as of December 31, 2025, indicating ongoing control deficiency.
NASDAQ: RNAZ Transcode Therapeutics, Inc. 10-Q

Transcode adds two clinical programs via acquisition and licensing, extends cash runway to year-end 2026

Filed May 15, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade RNAZ commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 25, 2026 9:20 AM